Advances in Respiratory Medicine

Advances in Respiratory Medicine is the open-access, peer-reviewed journal of the Polish Respiratory Society, founded in 1926 with publication history spanning several name changes and now co-published with MDPI, with a 2025 Journal Impact Factor of 4.5《呼吸医学进展》（Advances in Respiratory Medicine）是波兰呼吸医学会的同行评审开放获取期刊，1926 年创办，历经多次更名，现由（MDPI）合作出版，2025 年影响因子为 4.5。

Scope

• The journal publishes peer-reviewed original research articles, short communications, case reports and recommendations of the Polish Respiratory Society concerning diagnosis and treatment of lung diseases该刊发表同行评审的原创研究论文、短讯、病例报告及波兰呼吸医学会关于肺部疾病诊断与治疗的建议。
• It covers the field of pneumonology, allergology, oncology, immunology and infectious diseases of the respiratory system收稿范围涵盖呼吸病学、变态反应学、肿瘤学、免疫学与呼吸系统感染性疾病。
• Editorials, postgraduate education articles, letters and book reviews are also published期刊还刊发社论、研究生教育文章、读者来信与书评。
• Researchers are encouraged to submit mechanistic, translational and clinical studies addressing pressing respiratory questions该刊欢迎针对呼吸系统关键问题的机制、转化与临床研究投稿。
• Special issues bring together themed collections on chronic airway disease, post-COVID lung function and other priorities期刊通过专题专辑聚焦慢性气道疾病、新冠后肺功能与其他重点议题。
• All articles are published under a Creative Commons CC BY 4.0 licence as a fully open-access journal所有文章以（Creative Commons CC BY 4.0）许可发布，为完全开放获取期刊。

History

• The journal traces its roots to Gruźlica, founded in Poland in 1909 by Józef Gruby, with Polish-language annual volumes into the mid-twentieth century该刊可追溯至 1909 年由波兰结核病学家（Józef Gruby）创办的波兰语期刊（Gruźlica），20 世纪中叶以波兰语年刊形式出版。
• In 1962 the journal was renamed Gruźlica i Choroby Płuc, with subsequent name changes in 1975-76 to Pneumonologia i Alergologia Polska1962 年该刊更名为（Gruźlica i Choroby Płuc），1975-1976 年再次更名为《Pneumonologia i Alergologia Polska》。
• In 2016 the title became the English-language Advances in Respiratory Medicine, and on 1 July 2022 the publishing partnership transferred from Via Medica to MDPI2016 年该刊启用英文版现名《Advances in Respiratory Medicine》，2022 年 7 月 1 日出版合作由（Via Medica）转至（MDPI）。
• The journal is registered with ISSN 2451-4934 (print) and eISSN 2543-6031, is published bimonthly by MDPI in Basel and is owned by the Polish Respiratory Society该刊印刷版 ISSN 2451-4934，电子 ISSN 2543-6031，由位于巴塞尔的（MDPI）以双月刊出版，所有权属于波兰呼吸医学会。
• It has been indexed in MEDLINE, PubMed and PMC, and on the ESCI side of Web of Science since 2016该刊自 2016 年起被（MEDLINE）、（PubMed）、（PMC）以及（Web of Science）的（ESCI）收录。
• Its 2025 Journal Impact Factor is 4.5, with 2.3 in 2024, and 2025 downloads exceeded 125,284submission-to-first-decision time averages 22.9 days and acceptance-to-publication around 3.6 days 2025 年影响因子为 4.5，2024 年为 2.3；2025 年浏览量超过 12.53 万次；投稿至首决中位时间 22.9 天，接受至发表中位时间约 3.6 天。
• Editorial leadership includes researchers representing the National Research Institute of Tuberculosis and Lung Diseases in Warsaw编辑团队包含华沙国家结核病与肺部疾病研究所的研究人员。

Editors

• Adam Barczyk is Editor-in-Chief, with clinical and research interests in obstructive lung disease现任主编为（Adam Barczyk），临床与研究方向聚焦阻塞性肺疾病。
• He collaborates with a Deputy Editor and Section Editors covering allergy, oncology, infectious diseases and physiology of the respiratory system他与副主编及分管变态反应、肿瘤、感染、呼吸生理的板块编辑一起负责稿件组织。
• The journal's editorial board comprises clinicians and researchers associated with Polish and international respiratory medicine units编委由波兰及国际呼吸医学单位的临床医师与研究者组成。
• Editorial policies and recommendations of the Polish Respiratory Society form part of the publication pipeline编辑方针结合波兰呼吸医学会的建议与决策。
• Manuscripts undergo single-blind peer review under MDPI's editorial workflows稿件在（MDPI）编辑流程下接受单盲同行评审。